Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabindran, S. K.
Right arrow Articles by Greenberger, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabindran, S. K.
Right arrow Articles by Greenberger, L. M.
[Cancer Research 60, 47-50, January 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein1

Sridhar K. Rabindran2, Douglas D. Ross, L. Austin Doyle, Weidong Yang and Lee M. Greenberger

Oncology & Immunoinflammatory Research, Wyeth-Ayerst Research, Pearl River, NY 10965 [S. K. R., L. M. G.]; Greenebaum Cancer Center of the University of Maryland, Baltimore, Maryland 21201 [D. D. R., L. A. D., W. Y.]; Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 [D. D. R., L. A. D.]; and Baltimore Veterans Medical Center, Department of Veterans Affairs, Baltimore, Maryland 21201 [D. D. R.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Fumitremorgin C (FTC) is a potent and specific chemosensitizing agent in cell lines selected for resistance to mitoxantrone that do not overexpress P-glycoprotein or multidrug resistance protein. The gene encoding a novel transporter, the breast cancer resistance protein (BCRP), was recently found to be overexpressed in a mitoxantrone-selected human colon cell line, S1-M1–3.2, which was used to identify FTC. Because the drug-selected cell line may contain multiple alterations contributing to the multidrug resistance phenotype, we examined the effect of FTC on MCF-7 cells transfected with the BCRP gene. We report that FTC almost completely reverses resistance mediated by BCRP in vitro and is a pharmacological probe for the expression and molecular action of this transporter.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Multidrug resistance (MDR)3 is a common phenomenon in cancer patients, and it limits the effectiveness of chemotherapy (1) . In experimental systems, selection for resistance to a single cancer chemotherapeutic agent often results in cross-resistance to a variety of structurally and functionally diverse molecules (2) . Although the mechanistic basis for this phenomenon is complex, the overexpression of ABC transporters is often associated with this phenotype. Among the 33 genes predicted to encode human ABC transporters (3) , 5 mediate MDR when transfected into drug-sensitive cells: P-gp/MDR1 (4 , 5) , the MRP (6, 7, 8) and its homologues cMOAT/MRP2 (9) and MRP3 (10) , and a newly reported transporter, the BCRP4 (13) . These proteins mediate resistance to such commonly used chemotherapeutic drugs as doxorubicin, mitoxantrone, etoposide, paclitaxel, and vincristine. However, the exact cross-resistance profile for each transporter is distinct, although overlapping. These membrane-embedded proteins are thought to act as drug efflux pumps, preventing the cytotoxic agent from reaching lethal levels within the cells.

Reversal of MDR is a major goal in the clinical management of cancer. Pharmacological inhibition of the ABC transporters can be expected to resensitize cells to the action of antitumor agents. Inhibitors of P-gp (2 , 14) and MRP (15) have been reported, and P-gp reversal agents are being tested in the clinic (14 , 16) . These agents have also served as valuable tools for understanding the interaction of small molecules with ABC transporters. Recently, FTC, a novel chemosensitizing agent, was identified and shown to reverse drug resistance in a mitoxantrone-selected human colon carcinoma cell line (S1-M1–3.2) that does not overexpress P-gp or MRP (17) . S1-M1–3.2 cells, like other mitoxantrone-selected lines, have recently been shown to overexpress BCRP mRNA (11 , 18) . In this cell line, FTC reversed resistance to mitoxantrone, doxorubicin, and topotecan, but not to paclitaxel (17) . FTC was also highly effective on other drug selected cell lines overexpressing BCRP: MCF-7 breast cancer cells selected in mitoxantrone, MCF-7 cells selected in doxorubicin plus verapamil (17) , and 8226 multiple myeloma cells selected in mitoxantrone (19) . Reversal was associated with an increase in the amount of drug accumulated by the resistant cells (17 , 19) . These data suggest that FTC resensitizes drug-resistant cells by inhibiting BCRP-mediated drug transport. However, other mechanisms of resistance also exist in the drug selected cells, including alterations in topoisomerase activity (17 , 19 , 20) , and FTC may overcome resistance through these mechanisms. We therefore evaluated the activity of FTC in cells transfected with BCRP to determine specifically whether FTC can reverse resistance mediated by this transporter.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cell Culture.
MCF-7 cells transfected with the pcDNA3 vector (MCF-7/pcDNA3) or the BCRP expression construct (MCF-7/BCRP) clone 8 were obtained as previously reported (13) and were cultured in RPMI 1640 medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% FBS (Life Technologies), 50 µg/ml gentamicin (Life Technologies), and 100 µg/ml G418 (Geneticin, Life Technologies) at 37oC, under 7% CO2. Cells were passaged once per week. MCF-7/BCRP clone 8 cells are resistant to mitoxantrone, daunorubicin, and doxorubicin, compared with vector-transfected cells, but not to cis-platinum, paclitaxel, or vincristine (13) .

Cytotoxicity Assays.
Procedures were carried out as described previously (17) . Briefly, cells were plated in 96-well microtiter dishes (10,000 cells per well) in medium containing 5% FBS. After 4–6 h, dilutions of the antitumor agent (Sigma Chemical Co., St. Louis, MO) were added, along with FTC. Cell survival after 3 days of growth was determined using the sulforhodamine B assay. EC50s (drug dose causing 50% inhibition of cell growth, compared with untreated cells) were determined from the cytotoxicity curves.

Measurement of Intracellular Drug Accumulation.
The intracellular accumulation and retention of BBR 3390 (kindly provided by M. Hacker, Grand Valley State University, Allendale, MI) was determined using flow cytometry. Cells cultured in 25-cm2 tissue culture flasks were exposed to BBR 3390 (5 µM) for up to 120 min at 37oC (accumulation phase) or exposed to the drug for 120 min, washed in ice-cold saline, and then exposed to prewarmed culture medium in the absence of the drug at 37oC (retention phase). At various time intervals, cells were collected by trypsinization, and intracellular drug content was determined by fluorescence analysis (488-nm excitation, 525-nm emission) in a FACScan instrument (Becton Dickinson, Mountain View, CA). Where FTC was used, accumulation and retention times were 60 and 30 min, respectively, and cells were pretreated with FTC for 15 min at 37oC prior to the addition of BBR 3390. For drug retention analyses with daunorubicin, cells were collected by trypsinization, counted, and incubated in 12 x 75-mm tubes with 1 µM of the drug at 37°C (1 x 106 cells/tube). After 2 h, the cells were washed in ice-cold PBS and incubated in medium without the drug for 1 h at 37oC. Both incubations were carried out in the absence or presence of FTC (1 or 5 µM). Cells were washed three times in PBS containing 5% FBS and analyzed by flow cytometry (FACSort, Becton Dickinson). In all fluorescence assays, parallel samples were stored on ice to control for nonspecific binding of the drug to the plasma membranes. The fluorescence produced by these samples was subtracted from the experimental values. For radioactive drug retention assays, cells were plated in 24-well dishes (2–2.5 x 105 cells/well). The following day, the growth medium was replaced with medium containing 1 µM [14C] doxorubicin (66 mCi/mmol, Amersham). Cells were incubated for 2 h at 37oC, washed, and incubated in medium without the drug for 1 h. Where applicable, cells were treated with FTC (1 or 5 µM) during both incubations. The wells were washed twice with PBS, solubilized in 2 N NaOH, and counted in a scintillation counter. Protein content was determined using a modified Lowry assay (Bio-Rad, Richmond, CA).


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
MCF-7 cells overexpressing BCRP are resistant to mitoxantrone, daunorubicin, and doxorubicin, but not to cis-platinum, paclitaxel, or vincristine compared with vector-transfected cells (13) . Consistent with the drug resistance profile of the mitoxantrone selected S1-M1–3.2 cells, we observe here that MCF-7/BCRP cells are also cross-resistant to topotecan (Fig. 1)Citation . The reversal activity of FTC in MCF-7/BCRP cells was determined by using a fixed dose of the compound in combination with increasing doses of antitumor drugs (Fig. 1Citation and Table 1Citation ). FTC (5 µM) potentiated the toxicity of mitoxantrone (29.4-fold), doxorubicin (6.6-fold), and topotecan (6.5-fold). No activity was detected with paclitaxel (1.1-fold). These findings closely parallel the activity of FTC in three drug-selected cell lines that overexpress BCRP (17) . As indicated by the maximum DMF values (Table 1)Citation , almost a complete reversal of resistance was obtained for mitoxantrone and doxorubicin. FTC also enhanced the toxicity of mitoxantrone and topotecan in vector-transfected MCF-7 cells (2.5–5.6 fold). As a consequence of this effect, FTC reduced the IC50 of topotecan in BCRP-overexpressing cells below that observed in the untreated vector-transfected cells (Fig. 1)Citation , and the observed DMF exceeded the expected maximum DMF value. This has been previously observed in MCF-7 cells (17) and in two non-small cell lung carcinoma cell lines (H460 and A549) that were not selected for resistance to chemotherapeutic drugs.5 The activity of FTC on vector-transfected MCF-7 cells is most probably due to the known low level of expression of BCRP in the parental MCF-7 cells (18) , and it suggests that intrinsic resistance to mitoxantrone occurs in some cell lines in the absence of drug selection. However, we cannot rule out the possibility that a second, FTC-sensitive, mechanism of drug resistance may exist in MCF-7 cells.



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Reversal activity of FTC. MCF-7/BCRP cells ({blacktriangleup}, {triangleup}) and vector-transfected cells ({blacksquare}, {square}) were cultured in the absence ({blacktriangleup}, {blacksquare}) or presence ({triangleup}, {square}) of 5-µM FTC, along with increasing doses of four antitumor agents: mitoxantrone (A), doxorubicin (B), topotecan (C), and paclitaxel (D). Cell survival was determined after 3 days using the sulforhodamine B assay. SDs (not shown) were <10%.

 

View this table:
[in this window]
[in a new window]

  		Table 1 Activity of FTC in BCRP-transfected cells

MCF-7/BCRP or vector-transfected cells were cultured for 3 days with 5 µM FTC along with increasing doses of the indicated antitumor agents (triplicate points per dose). Cell survival was determined by the sulforhodamine B assay and EC50 values were determined from the cytotoxicity curves. For paclitaxel, EC30s (dose producing 30% inhibition of cell proliferation) were calculated because the shape of the cytotoxicity curves precluded estimation of EC50s (Fig. 1)Citation . The DMF is the ratio of EC50 values (EC30s for paclitaxel) obtained in the absence and presence of the reversal agent. Maximum expected DMF values (shown in parentheses) are the ratios of EC50s (EC30s for paclitaxel) of resistant and sensitive cells in the absence of the reversal agent. This is achieved when reversal is complete and is equivalent to the relative resistance.

 
Previously, transfection of BCRP cDNA in MCF-7 cells was shown to result in a reduced accumulation and retention of daunorubicin and an ATP-dependent enhancement of rhodamine 123 efflux (13) . To investigate the mechanism of reversal activity by FTC, we measured the intracellular content of BBR 3390, a fluorescent aza-anthrapyrazole, previously shown to be transported out of mitoxantrone-resistant cells (19) . For these experiments, cells were incubated with the agent (accumulation phase) or exposed to the drug, washed, and incubated in medium without the drug (retention phase). Intracellular BBR 3390 content was determined by fluorescence measurements. We first examined the kinetics of BBR 3390 accumulation and retention in BCRP-overexpressing and vector-transfected cells. MCF-7/BCRP cells showed a decrease in steady-state accumulation of the drug compared with the vector-transfected control (70% reduction at 120 min; Fig. 2ACitation ). After removal of the drug at 120 min, BBR 3390 fluorescence was reduced to background levels in BCRP-overexpressing cells within another 30 min, whereas vector-transfected cells retained 41% of the fluorescence at the same time point. We then determined the effect of FTC on intracellular BBR 3390 content. In the accumulation phase, untreated MCF-7/BCRP cells contained 18% of the fluorescence of the vector-transfected cells; FTC increased this 2.8-fold to 45% of the level seen in the corresponding vector controls (Fig. 2B)Citation . The reversal agent had a more dramatic effect in the retention phase. Here, BBR 3390 fluorescence was undetectable in untreated MCF-7/BCRP cells, and FTC increased this to 51% of the levels seen in the corresponding vector-control samples. No effect of FTC was observed in vector-transfected MCF-7 cells during the drug accumulation or the retention phases. We also examined the pharmacokinetics of daunorubicin and doxorubicin, two drugs to which the BCRP-overexpressing MCF-7 cells are resistant (13) . The intracellular content of the antitumor agents 1 h after removal of the agents from the medium was determined. Daunorubicin retention was measured by fluorescence analysis; [14C] doxorubicin retention was measured by scintillation counting. The use of a radiolabeled drug allowed us to examine the possibility of self-quenching, a problem inherent in fluorescence-based assays at high drug concentrations. MCF-7/BCRP cells retained reduced amounts of both drugs, compared with the vector-transfected cells (45–52%; Fig. 3Citation ). FTC treatment increased the amount of daunorubicin (1.8–2.3 fold) and [14C]-doxorubicin (1.8-fold) retained by the cells, compared with untreated cells. The increase in drug retention by FTC brought the level close to that seen in the vector controls. No effect of FTC was observed in the cells transfected with the vector alone. We were unable to observe decreased retention of [14C] mitoxantrone in MCF-7/BCRP cells compared with the vector control and, therefore, could not study the effect of FTC on mitoxantrone transport. This may be due to the high concentration of mitoxantrone required for the analysis (1 µM), the relatively low levels of drug resistance of the BCRP-overexpressing cells, and the tendency of mitoxantrone to bind nonspecifically to cellular proteins. Another possible explanation is that complete reconstitution of the mitoxantrone resistance phenotype will require the coexpression of other ABC transporters. Unlike P-gp and MRP, which contain two sets of transmembrane domains and two ATP binding sequences, BCRP structurally resembles a half-transporter because it contains only a single putative transmembrane region and ATP-binding motif. BCRP may, therefore, participate in drug resistance via a multiprotein transporter complex (11, 12, 13) .



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Measurement of intracellular BBR 3390 content. A, time course of BBR 3390 accumulation and retention. MCF-7 cells transfected with the vector (•) or with the BCRP expression construct ({blacksquare}) were incubated with BBR 3390 or incubated with the drug, washed, and incubated in medium without the drug. Samples were collected at various times and analyzed by flow cytometry. Arrow, the time point at which BBR 3390 was washed from the cells. B, effect of FTC on BBR 3390 accumulation and retention. MCF-7 cells transfected with the vector (left panel) or the BCRP cDNA (right panel) were incubated with 5-µM BBR 3390 in the absence (open bars) or presence (solid bars) of 10 µM FTC. Parallel samples were washed and incubated in medium without BBR 3390 (without or with FTC) for an additional 30 min. The cells were collected and analyzed by flow cytometry. The mean fluorescence of duplicate samples is shown along with the range.

 


View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of FTC on antitumor drug retention. MCF-7/BCRP and vector-transfected cells were incubated in medium containing daunorubicin (A) or [14C] doxorubicin (B), washed, and incubated in the absence of drug. The cells were then washed and analyzed by flow cytometry (daunorubicin) or scintillation counting (doxorubicin). All incubations were done in the absence (open bars) or presence (cross-hatched bars, 1 µM; solid bars, 5 µM) of FTC. For daunorubicin, the data shown represents the mean channel number of duplicate points. For doxorubicin, the results were normalized to the protein content of the samples, and the graph represents the mean of triplicate points. SDs are shown.

 
Although these data clearly suggest that FTC inhibits the function of BCRP, we cannot conclude that FTC directly interacts with this protein. However, this is the most likely possibility because FTC is a planar, multi-ring structure like mitoxantrone and doxorubicin and therefore may compete with these molecules for the binding sites on the transporter. This mechanism would be similar to P-gp, where it has been shown that inhibitors and substrates that are transported by P-gp directly interact with the transporter protein (2) . Competition studies between FTC and chemotherapeutic drugs in BCRP-containing membrane vesicles or whole cells may resolve this issue. Determination of the structure of FTC bound to BCRP will provide insights into the molecular interactions between other chemotherapeutic drugs and BCRP. For these purposes, the relative simplicity of BCRP compared to the other larger ABC transporters make it an ideal model system to study drug transport mediated by these proteins.

In summary, FTC resensitizes BCRP-expressing cells to mitoxantrone, doxorubicin, and topotecan cytotoxicity. Using probes for the cloned gene and FTC as a potent and selective pharmacological tool, it will be possible to evaluate the clinical role of BCRP in cancer and address the feasibility of reversing drug resistance mediated by this transporter. In addition, a detailed study of the possible interaction between FTC and BCRP will provide further understanding of the molecular basis of drug transport.


   ACKNOWLEDGMENTS
 
We thank S. Carter for assistance in the fluorescence analyses.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by a Veteran’s Affairs Merit Review (to D. D. R.). Back

2 To whom requests for reprints should be addressed, at Wyeth-Ayerst Research, Building 200, Room 4608, 401 North Middletown Road, Pearl River, NY 10965. Phone: (914) 732-5438; Fax: (914) 732-5557; E-mail: Rabinds{at}war.wyeth.com Back

3 The abbreviations used are: MDR, multidrug resistance; ABC, ATP binding cassette; BCRP, breast cancer resistance protein; DMF, dose-modifying factor; FTC, fumitremorgin C; MRP, MDR protein; P-gp, P-glycoprotein; FBS, fetal bovine serum. Back

4 BCRP is also known as the mitoxantrone resistance gene product (MXR; Ref. 11 ) or placenta-specific ABC transporter (ABCP; Ref. 12 ). Back

5 S. E. Bates, personal communication. Back

Received 9/ 8/99. Accepted 11/12/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Young R. C. Drug resistance: the clinical problem Ozols R. F. eds. . Drug Resistance in Cancer Therapy, : 1-12, Kluwer Academic Press Boston 1989.
  2. Greenberger L. M., Cohen D., Horwitz S. B. In vitro models of multiple drug resistance Goldstein L. J. Ozols R. F. eds. . Anticancer Drug Resistance, : 69-106, Kluwer Academic Publishers Norwell, MA 1994.
  3. Allikmets R., Gerrard B., Hutchinson A., Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Human Mol. Genet., 5: 1649-1655, 1996.[Abstract/Free Full Text]
  4. Gros P., Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (Lond.), 232: 728-731, 1986.
  5. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA, 84: 3004-3008, 1987.[Abstract/Free Full Text]
  6. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P. C., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases in resistance to natural products. Cancer Res., 54: 357-361, 1994.[Abstract/Free Full Text]
  7. Zaman G. J. R., Flens M. J., van Leusden M. R., de Haas M., Mulder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J., Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pum. p. Proc. Natl. Acad. Sci. USA, 91: 8822-8826, 1994.[Abstract/Free Full Text]
  8. Breuninger L. M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S. A., Kruh G. D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res., 55: 5342-5347, 1995.[Abstract/Free Full Text]
  9. Kawabe T., Chen Z. S., Wada M., Uchiumi T., Ono M., Akiyama S., Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett., 456: 327-331, 1999.[Medline]
  10. Kool M., van der Linden M., de Haas M., Scheffer G. L., de Vree J. M., Smith A. J., Jansen G., Peters G. J., Ponne N., Scheper R. J., Elferink R. P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 96: 6914-6919, 1999.[Abstract/Free Full Text]
  11. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transporters. Cancer Res., 59: 8-13, 1999.[Abstract/Free Full Text]
  12. Allikmets R., Schriml L. M., Hutchinson A., Romano-Spica V., Dean M. A placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.[Abstract/Free Full Text]
  13. Doyle L. A., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.[Abstract/Free Full Text]
  14. Sikic B. I. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol., 34: 40-47, 1997.[Medline]
  15. Lautier D., Canitrot Y., Deeley R. G., Cole S. P. C. Multidrug resistance mediated by the multidrug resistance protein gene. Biochem. Pharmacol., 52: 967-977, 1996.[Medline]
  16. Atadja P., Watanabe T., Xu H., Cohen D. PSC-833 a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev., 17: 163-168, 1998.[Medline]
  17. Rabindran S. K., He H., Singh M., Brown E., Collins K. I., Annable T., Greenberger L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 58: 5850-5858, 1998.[Abstract/Free Full Text]
  18. Ross D. D., Yang W., Abruzzo L. V., Dalton W. S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S. P. C., Doyle L. A. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cells. J. Natl. Cancer Inst., 91: 429-433, 1999.[Abstract/Free Full Text]
  19. Hazlehurst L. A., Foley N. E., Gleason-Guzman M. C., Hacker M. P., Cress A. E., Greenberger L. W., De Jong M. C., Dalton W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res., 59: 1021-1028, 1999.[Abstract/Free Full Text]
  20. Chen Y-N., Mickley L. A., Schwartz A. M., Acton E., Hwang J., Fojo A. T. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 265: 10073-10080, 1990.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Solazzo, O. Fantappie, M. D'Amico, C. Sassoli, A. Tani, G. Cipriani, C. Bogani, L. Formigli, and R. Mazzanti
Mitochondrial Expression and Functional Activity of Breast Cancer Resistance Protein in Different Multiple Drug-Resistant Cell Lines
Cancer Res., September 15, 2009; 69(18): 7235 - 7242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhang, Y. Byun, Y. R. Ren, J. O. Liu, J. Laterra, and M. G. Pomper
Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay
Cancer Res., July 15, 2009; 69(14): 5867 - 5875.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. E. Bram, Y. Adar, N. Mesika, M. Sabisz, A. Skladanowski, and Y. G. Assaraf
Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2
Mol. Pharmacol., May 1, 2009; 75(5): 1149 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Yin, P. Castagnino, and R. K. Assoian
ABCG2 Expression and Side Population Abundance Regulated by a Transforming Growth Factor {beta}-Directed Epithelial-Mesenchymal Transition
Cancer Res., February 1, 2008; 68(3): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhang, J. P. Bressler, J. Neal, B. Lal, H.-E. C. Bhang, J. Laterra, and M. G. Pomper
ABCG2/BCRP Expression Modulates D-Luciferin Based Bioluminescence Imaging
Cancer Res., October 1, 2007; 67(19): 9389 - 9397.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, and A. R. Oseroff
The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2
Clin. Cancer Res., April 15, 2007; 13(8): 2463 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Weiss, J. Rose, C. H. Storch, N. Ketabi-Kiyanvash, A. Sauer, W. E. Haefeli, and T. Efferth
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs
J. Antimicrob. Chemother., February 1, 2007; 59(2): 238 - 245.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Turner, J. L. Gump, C. Zhang, J. M. Cook, D. Marchion, L. Hazlehurst, P. Munster, M. J. Schell, W. S. Dalton, and D. M. Sullivan
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Blood, December 1, 2006; 108(12): 3881 - 3889.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev, October 1, 2006; 86(4): 1179 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. J. Henrich, H. R. Bokesch, M. Dean, S. E. Bates, R. W. Robey, E. I. Goncharova, J. A. Wilson, and J. B. McMahon
A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
J Biomol Screen, March 1, 2006; 11(2): 176 - 183.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7764 - 7772.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X.-f. Zhou, X. Yang, Q. Wang, R. A. Coburn, and M. E. Morris
EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES
Drug Metab. Dispos., August 1, 2005; 33(8): 1220 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. T. Budak, O. S. Alpdogan, M. Zhou, R. M. Lavker, M.A. M. Akinci, and J. M. Wolosin
Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells
J. Cell Sci., April 15, 2005; 118(8): 1715 - 1724.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H.G.P. Raaijmakers, E. P.L.M. de Grouw, L. H.H. Heuver, B. A. van der Reijden, J. H. Jansen, R. J. Scheper, G. L. Scheffer, T. J.M. de Witte, and R. A.P. Raymakers
Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38- Cells in Acute Myeloid Leukemia
Clin. Cancer Res., March 15, 2005; 11(6): 2436 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, et al.
Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2-Mediated Drug Resistance
Cancer Res., February 15, 2005; 65(4): 1541 - 1546.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Ueda, S. Brenner, H. L. Malech, S. M. Langemeijer, S. Perl, M. Kirby, O. A. Phang, A. E. Krouse, R. E. Donahue, E. M. Kang, et al.
Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene: FORCED EXPRESSION CONFERS AN SP PHENOTYPE AMONG HEMATOPOIETIC STEM CELL PROGENY IN VIVO
J. Biol. Chem., January 14, 2005; 280(2): 991 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P.L. R. Ee, X. He, D. D. Ross, and W. T. Beck
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference
Mol. Cancer Ther., December 1, 2004; 3(12): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Imai, S. Tsukahara, S. Asada, and Y. Sugimoto
Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance
Cancer Res., June 15, 2004; 64(12): 4346 - 4352.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Krishnamurthy, D. D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K. E. Mercer, B. Sarkadi, B. P. Sorrentino, and J. D. Schuetz
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
J. Biol. Chem., June 4, 2004; 279(23): 24218 - 24225.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. Kodama, M. Suga, and A. Ochiai
Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2004; 10(5): 1691 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Nakanishi, L. A. Doyle, B. Hassel, Y. Wei, K. S. Bauer, S. Wu, D. W. Pumplin, H.-B. Fang, and D. D. Ross
Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis
Mol. Pharmacol., December 1, 2003; 64(6): 1452 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. L. Volk and E. Schneider
Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter
Cancer Res., September 1, 2003; 63(17): 5538 - 5543.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo, and Y. Sugimoto
Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens
Mol. Pharmacol., September 1, 2003; 64(3): 610 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z.-S. Chen, R. W. Robey, M. G. Belinsky, I. Shchaveleva, X.-Q. Ren, Y. Sugimoto, D. D. Ross, S. E. Bates, and G. D. Kruh
Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport
Cancer Res., July 15, 2003; 63(14): 4048 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Janvilisri, H. Venter, S. Shahi, G. Reuter, L. Balakrishnan, and H. W. van Veen
Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis
J. Biol. Chem., May 30, 2003; 278(23): 20645 - 20651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Allen, S. C. van Dort, M. Buitelaar, O. van Tellingen, and A. H. Schinkel
Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein
Cancer Res., March 15, 2003; 63(6): 1339 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S.-I. Akiyama, and M. Baba
Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors
Mol. Pharmacol., January 1, 2003; 63(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Sugimoto, S. Tsukahara, Y. Imai, Y. Sugimoto, K. Ueda, and T. Tsuruo
Reversal of Breast Cancer Resistance Protein-mediated Drug Resistance by Estrogen Antagonists and Agonists
Mol. Cancer Ther., January 1, 2003; 2(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Ozvegy, A. Varadi, and B. Sarkadi
Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. MODULATION OF SUBSTRATE SPECIFICITY BY A POINT MUTATION
J. Biol. Chem., December 6, 2002; 277(50): 47980 - 47990.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. D. Allen, A. van Loevezijn, J. M. Lakhai, M. van der Valk, O. van Tellingen, G. Reid, J. H. M. Schellens, G.-J. Koomen, and A. H. Schinkel
Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C
Mol. Cancer Ther., April 1, 2002; 1(6): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. D. Allen and A. H. Schinkel
Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2)
Mol. Cancer Ther., April 1, 2002; 1(6): 427 - 434.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. F. Faneyte, P. M. P. Kristel, M. Maliepaard, G. L. Scheffer, R. J. Scheper, J. H. M. Schellens, and M. J. van de Vijver
Expression of the Breast Cancer Resistance Protein in Breast Cancer
Clin. Cancer Res., April 1, 2002; 8(4): 1068 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. W. Scharenberg, M. A. Harkey, and B. Torok-Storb
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors
Blood, January 15, 2002; 99(2): 507 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Maliepaard, M. A. van Gastelen, A. Tohgo, F. H. Hausheer, R. C. A. M. van Waardenburg, L. A. de Jong, D. Pluim, J. H. Beijnen, and J. H. M. Schellens
Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918
Clin. Cancer Res., April 1, 2001; 7(4): 935 - 941.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al.
The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux
Cancer Res., January 1, 2001; 61(2): 739 - 748.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. W. Robey, W. Y. Medina-Pérez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A. M. Senderowicz, D. D. Ross, and S. E. Bates
Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer Cells
Clin. Cancer Res., January 1, 2001; 7(1): 145 - 152.
[Abstract] [Full Text]

Home page
 BloodHome page
D. D. Ross, J. E. Karp, T. T. Chen, and L. A. Doyle
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
Blood, July 1, 2000; 96(1): 365 - 368.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabindran, S. K.
Right arrow Articles by Greenberger, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabindran, S. K.
Right arrow Articles by Greenberger, L. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online